NDA 214900 · Glaxosmithkline
Brexafemme
Ibrexafungerp Citrate · Oral
NovelPriority reviewCDER novel approval, Jun 1, 2021: To treat vulvovaginal candidiasis
Last checked: Nov 20, 2026Latest source record: Jul 24, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Jun 1, 2021
Approved uses
2
Original approval plus efficacy supplements
Registered trials
16
7 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. FDA's summary: To treat vulvovaginal candidiasis
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 30, 2022 Supplement 2 · Efficacy · priority review LetterLabelReview
- Jun 1, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
1 products under this application
- BREXAFEMME · IBREXAFUNGERP CITRATE EQ 150MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ibrexafungerp" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal CandidiasisPivotal-lookingCompleted
Scynexis, Inc.Industry
NCT03987620 · 455 participants · Start Jun 7, 2019 · Primary completion Mar 29, 2020
Drug: Ibrexafungerp; Placebo · For: Candida Vulvovaginitis
Sites: Mesa, Arizona; Lakewood, Colorado; New Haven, Connecticut · 41 sites in all
- Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)Pivotal-lookingCompleted
Scynexis, Inc.Industry
NCT04029116 · 440 participants · Start Oct 21, 2019 · Primary completion Sep 1, 2021
Drug: Fluconazole Tablet; IBREXAFUNGERP and 1 more · For: Recurrent Vulvovaginal Candidiasis
Sites: Phoenix, Arizona; San Diego, California; Lake Worth, Florida · 25 sites in all
- Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303)Pivotal-lookingCompleted
Scynexis, Inc.Industry
NCT03734991 · 376 participants · Start Jan 4, 2019 · Primary completion Aug 21, 2019
Drug: Ibrexafungerp; Placebo · For: Candida Vulvovaginitis
Sites: Birmingham, Alabama; Phoenix, Arizona; San Diego, California · 25 sites in all
- Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal TreatmentPivotal-lookingCompleted
Scynexis, Inc.Industry
NCT03059992 · 233 participants · Start Apr 1, 2017 · Primary completion Aug 25, 2023
Drug: Ibrexafungerp · For: Invasive Candidiasis; Mucocutaneous Candidiasis; Coccidioidomycosis and 7 more
Sites: Birmingham, Alabama; Sacramento, California; San Francisco, California · 37 sites in all
- Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal CandidiasisPivotal-lookingCompleted
Scynexis, Inc.Industry
NCT03253094 · 186 participants · Start Aug 1, 2017 · Primary completion May 4, 2018
Drug: Fluconazole; SCY-078 · For: Candida Vulvovaginitis
Sites: Birmingham, Alabama; Phoenix, Arizona; San Diego, California · 25 sites in all
- Ibrexafungerp for the Treatment of Complicated Vulvovaginal CandidiasisPivotal-lookingCompleted
Scynexis, Inc.Industry
NCT05399641 · 150 participants · Start May 1, 2022 · Primary completion May 16, 2023
Drug: Ibrexafungerp · For: Vulvovaginal Candidiasis
Sites: Phoenix, Arizona; San Diego, California; Miami, Florida · 25 sites in all
Scynexis, Inc.Industry
NCT02679456 · 96 participants · Start Nov 2015 · Primary completion Aug 5, 2016
Drug: SCY-078; Fluconazole · For: Vulvovaginal Candidiasis
Sites: Santo Domingo, Dominican Republic · 2 sites in all
- A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral FluconazolePivotal-lookingTerminated
Scynexis, Inc.Industry
NCT05178862 · 68 participants · Start Aug 3, 2022 · Primary completion Nov 7, 2025
Drug: SCY-078; Fluconazole and 1 more · For: Candidiasis, Invasive; Candidemia
Sites: Birmingham, Alabama; Tucson, Arizona; Sacramento, California · 101 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Ibrexafungerp for the treatment of vulvovaginal candidiasis: A systematic review and meta-analysis of randomized placebo-controlled trials.
Kow CS, Ramachandram DS, Hasan SS, et al. · J Mycol Med 2025 · Systematic Review, Meta-Analysis
- Oral Ibrexafungerp for Vulvovaginal Candidiasis Treatment: An Analysis of VANISH 303 and VANISH 306.
Goje O, Sobel R, Nyirjesy P, et al. · J Womens Health (Larchmt) 2023 · Clinical Trial, Research Support, Non-U.S. Gov't
- A phase 3, multicenter, randomized, placebo-controlled trial of monthly oral ibrexafungerp to reduce the incidence of recurrent vulvovaginal candidiasis.
Goje O, Azie NE, Angulo DA, et al. · Am J Obstet Gynecol 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
- Phase 2 Randomized Study of Oral Ibrexafungerp Versus Fluconazole in Vulvovaginal Candidiasis.
Nyirjesy P, Schwebke JR, Angulo DA, et al. · Clin Infect Dis 2022 · Clinical Trial, Phase II, Randomized Controlled Trial
- Efficacy and safety of oral ibrexafungerp in Chinese patients with vulvovaginal candidiasis: a phase III, randomized, double-blind study.
Wang X, Wang W, Li J, et al. · Infection 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis.
Spec A, Pullman J, Thompson GR, et al. · J Antimicrob Chemother 2019 · Clinical Trial, Phase II, Randomized Controlled Trial
Sponsor: GSK
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.